Log In
BCIQ
Print this Print this
 

UCART22

  Manage Alerts
Collapse Summary General Information
Company Cellectis S.A.
DescriptionChimeric antigen receptor (CAR)-modified allogeneic T cells
Molecular Target CD22
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphoblastic leukemia (ALL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/03/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today